Patents by Inventor Karl-Heinz Baringhaus

Karl-Heinz Baringhaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7211592
    Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.
    Type: Grant
    Filed: September 13, 2004
    Date of Patent: May 1, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
  • Patent number: 7208504
    Abstract: Benzotriazoles of formula I in which R1 to R8 have the abovementioned meanings and process for their preparation are described. The compounds show an inhibitory effect on hormone-sensitive lipase.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: April 24, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller, Hubert Heuer
  • Patent number: 7094794
    Abstract: Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for lowering the blood glucose and for the prevention and treatment of diabetes.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: August 22, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller
  • Publication number: 20050197348
    Abstract: The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs.
    Type: Application
    Filed: January 25, 2005
    Publication date: September 8, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Karl-Heinz Baringhaus
  • Publication number: 20050070533
    Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for lowering the blood glucose and for the prevention and treatment of diabetes.
    Type: Application
    Filed: July 27, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller
  • Publication number: 20050043373
    Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydrobenzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.
    Type: Application
    Filed: September 13, 2004
    Publication date: February 24, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
  • Publication number: 20040127484
    Abstract: Benzotriazoles of formula I 1
    Type: Application
    Filed: October 14, 2003
    Publication date: July 1, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller, Hubert Heuer
  • Publication number: 20030191161
    Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydrobenzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.
    Type: Application
    Filed: March 31, 2003
    Publication date: October 9, 2003
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
  • Patent number: 6596742
    Abstract: Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 in any optically isomeric form, and their physiologically acceptable salts, where R1 is C1-C6-alkyl, C3-C9-cycloalkyl, both of which may be unsubstituted or substituted, and R2 and R3 independently of one another are hydrogen, C6-C10-aryl, C3-C8-cycloalkyl, C6-C10-aryloxymethyl, O-benzyl, O—C6-C10-aryl, O—C3-C8-cycloalkyl, O—C1-C6-alkyl, SO2—NH—C1-C6-alkyl, SO2—NH-(2,2,6,6-tetramethylpiperidin-4-yl), SO2—NH—C3-C8-cycloalkyl, SO2—N(C1-C6-alkyl)2 or COX, where X is O—C1-C6-alkyl, NH—C1-C6-alkyl, NH—C3-C8-cycloalkyl or N(C1-C6-alkyl)2, with the proviso that the substitutents R2 and R3 may in some instances be unsubstituted or substituted and are not both simultaneously hydrogen. A process for their preparation, and their inhibitory effect on the hormone-sensitive lipase, HSL.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: July 22, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl Schoenafinger, Guenter Mueller, Karl-Heinz Baringhaus
  • Patent number: 6566390
    Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: May 20, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
  • Patent number: 6506778
    Abstract: The invention is directed to acylphenylurea derivatives and their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and a process for their preparation are described. The compounds are suitable, for example, for treating type II diabetes.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: January 14, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Elisabeth Defossa, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Heinz Baringhaus
  • Publication number: 20020151586
    Abstract: The invention is directed to acylphenylurea derivatives and their physiologically tolerated salts and physiologically functional derivatives.
    Type: Application
    Filed: June 8, 2001
    Publication date: October 17, 2002
    Inventors: Elisabeth Defossa, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Heinz Baringhaus
  • Publication number: 20020055523
    Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo [c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.
    Type: Application
    Filed: August 9, 2001
    Publication date: May 9, 2002
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
  • Patent number: 6369088
    Abstract: Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 are described, in which R1 is substituted C1-C6-alkyl and C3-C9-cycloalkyl, R2, R3, R4 and R5 are hydrogen, halogen, nitro, C1-C4-alkyl, C1-C9-alkyloxy, substituted C6-C10-aryl-C1-C4-alkyloxy, C6-C10-aryloxy, C6-C10-aryl, C3-C8-cycloalkyl or O—C3—C8-cycloalkyl, or 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR6-A-R7, with the proviso that R2, R3, R4 and R5 are not simultaneously hydrogen, and at least one of the radicals R2, R3, R4 or R5 is the radical 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR6-A-R7, wherein R6=hydrogen, C1-C4-alkyl or substituted C6-C10-aryl-C1-C4-alkyl, A=a single bond, COn, SOn or CONH, n=1 or 2, R7=hydrogen, substituted C1-C18-alkyl, C2-C18-alkenyl, C6-C10-aryl-C1-C4-alkyl, C5-C8-cycloalkyl-C1-C4-alkyl, C5-C8-cycloalkyl, C6-C10-aryl-C2-C6-alkenyl, C6-C10-aryl, biphenylyl, biphenylyl-C1-C4-alkyl, indanyl, or the group Het-(CH2)r—, wherein r&eq
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: April 9, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Karl Schoenafinger, Stefan Petry, Guenter Mueller, Karl-Heinz Baringhaus
  • Publication number: 20010031772
    Abstract: Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 are described, 1
    Type: Application
    Filed: March 6, 2001
    Publication date: October 18, 2001
    Inventors: Karl Schoenafinger, Stefan Petry, Guenter Mueller, Karl-Heinz Baringhaus
  • Patent number: 6093730
    Abstract: Novel isoquinoline-3-carboxamides of the formula I: ##STR1## in which R.sub.1 is hydrogen or chlorine, R.sup.2 is hydrogen, alkyl, alkoxy, chlorine, trifluoromethyl, hydroxyl, or benzyloxy which is optionally substituted, or fluoroalkoxy of the formula O--[CH.sub.2 ].sub.x --C.sub.f H.sub.(2f+1-g) F.sub.g, where x=0 or 1, f=1-5, and g=1 to (2f+1), R.sup.3 is hydrogen, alkyl, alkoxy, fluorine, chlorine, cyano, trifluoromethyl, hydroxyl, or benzyloxy which is optionally substituted, or fluoroalkoxy of the above formula, R.sup.4 and R.sup.5 are hydrogen, alkyl, fluorine, chlorine, bromine, trifluoromethyl, cyano, alkoxy, or fluoroalkoxy of the above formula, including the physiologically active salts, are strong prolyl-4-hydroxylase inhibitors which do not cause steatosis.
    Type: Grant
    Filed: October 19, 1998
    Date of Patent: July 25, 2000
    Assignee: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Klaus Weidmann, Karl-Heinz Baringhaus, Georg Tschank, Ulrich Werner
  • Patent number: 6020350
    Abstract: There are described 3-hydrixypyridine-2-carboxamidoesters of the formula ##STR1## their preparation, their use for the inhibition of collagen biosynthesis and their use as pharmaceuticals for the treatment of fibrotic disorders.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: February 1, 2000
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus Weidmann, Karl-Heinz Baringhaus, Georg Tschank, Martin Bickel
  • Patent number: 5874451
    Abstract: The invention relates to substituted propanolamine derivatives and their acid addition salts.Propanolamine derivatives of formula I, ##STR1## in which R.sup.1 to R.sup.8 have the meanings indicated in the specification, and their physiologically tolerable salts and processes for their preparation are described. The compounds are suitable, for example, as hypolipidemics.
    Type: Grant
    Filed: April 2, 1998
    Date of Patent: February 23, 1999
    Assignee: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Heiner Glombik, Alfons Enhsen, Werner Kramer, Karl-Heinz Baringhaus
  • Patent number: 5726305
    Abstract: The invention relates to substituted quinoline-2-carboxylic acid amides of the formula I ##STR1## their preparation and their use, and intermediates which are formed in the preparation of the compounds of the formula I. The compounds according to the invention are used as inhibitors of prolyl 4-hydroxylase and as pharmaceuticals (medicaments) for treatment of fibrotic diseases.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: March 10, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus Weidmann, Karl-Heinz Baringhaus, Georg Tschank, Martin Bickel
  • Patent number: 5719164
    Abstract: The invention relates to substituted quinoline-2-carboxylic acid amides of the formula I ##STR1## their preparation and their use, and intermediates which are formed in the preparation of the compounds of the formula I. The compounds according to the invention are used as inhibitors of prolyl 4-hydroxylase and as pharmaceuticals (medicaments) for treatment of fibrotic diseases.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: February 17, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus Weidmann, Karl-Heinz Baringhaus, Georg Tschank, Martin Bickel